Letrozole as a Prophylaxis From GTN for Complete Mole Patients

• Status: Active, not recruiting
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

Prophylactic use of aromatase inhibitor is effective in decreasing the incidence of Gestational Trophoblastic Neoplasia (GTN) in patients with complete hydatidiform mole (CHM)

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zagazig University
• Treatments: Letrozole

Criteria

Inclusion Criteria:

• Women were diagnosed to have CHM by ultrasound and confirmed by histopathological examination

Exclusion Criteria:

• Metastatic disease associated with HM at presentation, in which situation chemotherapy, rather than prophylactic treatment, as prescribed,

• Late diagnosis of CHM made only by histological examination of curetted material

• Uterine evacuation at another hospital and patient seen at the optimum patient care only for follow up